Headache News and Research

Latest Headache News and Research

FDA grants priority review for Alkermes' VIVITROL sNDA for opioid dependence

Alkermes, Inc. today announced that the supplemental New Drug Application (sNDA) for VIVITROL® (naltrexone for extended-release injectable suspension) for opioid dependence has been designated a priority review by the U.S. Food and Drug Administration (FDA).

25 May 2010

Biogen Idec to join global MS community to commemorate the second annual World MS Day

On May 26, Biogen Idec will join the global multiple sclerosis community to commemorate the second annual World MS Day. Biogen Idec is a leader in the fight against MS, bringing hope to the thousands of patients across the globe who benefit from the company's MS therapies and ongoing research programs.

25 May 2010

Bayer's Adalat XL product and Mylan's nifedipine extended release 60 mg not bioequivalent: Study

Bayer Inc. today responded to Professor Marvin Meyer's letter to the editor, entitled: "Critical questions concerning the validity of the Bayer study report of differences in bioavailability between 60 mg of nifedipine osmotic push-pull systems after fasted and fed administration" and published in the online edition of the International Journal of Clinical Pharmacology and Therapeutics. Bayer responded to the clinical relevance of the differences in formulation and dissolution behaviour and the delayed absorption of Mylan's extended release nifedipine.

25 May 2010

Salix Pharmaceuticals announces availability of Xifaxan tablets for reducing risk of overt HE recurrence

Salix Pharmaceuticals, Ltd. today announced the availability of Xifaxan (rifaximin) 550 mg tablets for the reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years of age or older. Those HE patients may now fill their Xifaxan 550 mg prescriptions in U.S. pharmacies and should speak with their doctors about this important treatment option.

24 May 2010

New findings on INTUNIV Extended Release Tablets presented at major psychiatric meeting

Shire plc, the global specialty biopharmaceutical company, today announced new findings on once-daily INTUNIV (guanfacine) Extended Release Tablets, the first selective alpha-2A agonist approved for the treatment of Attention Deficit Hyperactivity Disorder, at a major psychiatric meeting.

24 May 2010

Provectus to present further positive data from PV-10 Phase 2 clinical trial for metastatic melanoma at ASCO

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has announced further positive data on the first forty subjects in its Phase 2 clinical trial of PV-10 for metastatic melanoma, with an objective response ("OR") observed in 61% of subjects and a mean Progression Free Survival ("PFS") of at least 11.1 months among those subjects achieving an OR.

21 May 2010

Genentech to present new data for targeted cancer medicines at 46th ASCO

Genentech, Inc., a wholly owned member of the Roche Group, today announced that it will present new data for its targeted cancer medicines and the way they may be used in several different cancer types at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). Approximately 400 abstracts featuring Genentech and Roche's cancer medicines and investigational agents across 30 cancer types will be presented during the meeting that is taking place June 4 to 8, 2010 in Chicago.

21 May 2010

Exelixis reports interim data from XL184 phase 2 trial for recurrent glioblastoma at ASCO 2010

Exelixis, Inc. today reported promising interim data from an ongoing phase 2 trial of XL184 in patients with recurrent glioblastoma (GB), the most common and aggressive form of brain cancer. Dr. Patrick Wen from the Dana Farber Cancer Institute in Boston, MA will present the data in an Oral Session (Abstract #2006) on Saturday, June 5 at 5:00 p.m. at the 2010 Annual Meeting of the American Society of Clinical Oncology in Chicago.

21 May 2010

Data from Phase 3 clinical trials of PROVENGE in advanced prostate cancer to be presented at ASCO 2010

Dendreon Corporation today announced the upcoming presentation of data from integrated analyses of three Phase 3 PROVENGE (sipuleucel-T) clinical trials of an autologous cellular immunotherapy in advanced prostate cancer, to be presented at the annual meeting of the American Society of Clinical Oncology in Chicago on Monday, June 7 at 8:00 a.m. CT.

21 May 2010

Hendra virus infects a horse in south Queensland – authorities fear spread

A horse was put down at Tewantin, near Noosa and it was confirmed that it had Hendra virus infection. At present quarantine measures are being taken.

20 May 2010

AANS/CNS issue statement on Congress hearing of impact of concussions on high school athletes

On Thursday, May 20, 2010, the U.S. House of Representatives Committee on Education and Labor held a hearing to learn more about the impact of concussions on high school athletes and how the injury can impact academic achievement. A concussion is an injury to the brain that results in loss of normal brain function and is usually temporary.

20 May 2010

Research shows improved treatment of severe epilepsy reduces overall cost of the condition

Improved treatment of severe epilepsy could reduce the overall cost of the condition, according to research presented at the annual meeting of the International Society of Pharmacoeconomic Outcomes Research at the Hilton Atlanta in Atlanta, Georgia.

20 May 2010

FDA approves ZYMAXID ophthalmic solution for treatment of bacterial conjunctivitis

Allergan, Inc. today announced that the United States Food and Drug Administration has approved ZYMAXID (gatifloxacin ophthalmic solution) 0.5%, a topical fluoroquinolone anti-infective indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms; Haemophilus influenzae, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus mitis group, Streptococcus oralis, Streptococcus pneumonia.

20 May 2010

Studies suggest potent therapeutic effects of rufinamide in bipolar disorder, depressive and anxiety disorders

This study formulates the hypothesis that rufinamide, a drug so far used against epilepsy, may also be effective in bipolar disorder, depressive and anxiety disorders, panic disorder and obsessive-compulsive disorder, eating disorders, and substance use disorders. It is just an hypothesis based on two cases that needs to be confirmed by specific studies.

19 May 2010

Columbia Laboratories renews license and supply agreement with Merck Serono

Columbia Laboratories, Inc. has renewed its license and supply agreement with Merck Serono, a division of Merck KGaA, Darmstadt, Germany, for CRINONE (progesterone gel) for an additional five-year term. Under the existing agreement and the renewal, Merck Serono has marketing rights worldwide, except the United States.

18 May 2010

Final data from Open-Label studies of Cinryze in patients with HAE now available

ViroPharma Incorporated today announced the availability of final data from Open-Label studies of Cinryze (C1 Esterase Inhibitor [Human]) in preventing and treating attacks of hereditary angioedema on the U.S. National Institutes of Health's online clinical trial registry, www.clinicaltrials.gov.

18 May 2010

Canadian tourist bitten by a Katipo spider in New Zealand

A Canadian tourist suffered a serious heart inflammation called myocarditis after he was bitten by a poisonous spider when he went swimming nude in New Zealand.

13 May 2010

U.S. Well-Being Report for April 2010

The Gallup-Healthways Well-Being Index was a tie (63.3) for all-time overall well-being in April, revealing a continued recovery of American well-being despite continuing challenges and high unemployment. The only other time in 28 months of measurement the WBI reached 67 was in August 2009.

13 May 2010

Trubion Pharmaceuticals to present promising data from Phase 1 studies of SBI-087, SBI-087

Trubion Pharmaceuticals, Inc. today announced the acceptance of two Phase 1 data presentations on SBI-087 (PF-05230895) at the 2010 annual congress of the European League Against Rheumatism (EULAR) in Rome, Italy. Presentations will include promising data from a Phase 1 study of SBI-087 for the treatment of rheumatoid arthritis (RA) and a Phase 1 study of SBI-087 for the treatment of systemic lupus erythematosus (SLE). Copies of both abstracts are available at http://www.eular.org. SBI-087 is Trubion's next-generation CD20-directed small modular immunopharmaceutical (SMIP™) product candidate and is being developed in collaboration with Pfizer.

13 May 2010

Alexza Pharmaceuticals first-quarter net loss increases to $13.4 million

Alexza Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2010 and provided a business update.

11 May 2010

Headache News and Research

Latest Headache News and Research

FDA grants priority review for Alkermes' VIVITROL sNDA for opioid dependence

Biogen Idec to join global MS community to commemorate the second annual World MS Day

Bayer's Adalat XL product and Mylan's nifedipine extended release 60 mg not bioequivalent: Study

Salix Pharmaceuticals announces availability of Xifaxan tablets for reducing risk of overt HE recurrence

New findings on INTUNIV Extended Release Tablets presented at major psychiatric meeting

Provectus to present further positive data from PV-10 Phase 2 clinical trial for metastatic melanoma at ASCO

Genentech to present new data for targeted cancer medicines at 46th ASCO

Exelixis reports interim data from XL184 phase 2 trial for recurrent glioblastoma at ASCO 2010

Data from Phase 3 clinical trials of PROVENGE in advanced prostate cancer to be presented at ASCO 2010

Hendra virus infects a horse in south Queensland – authorities fear spread

AANS/CNS issue statement on Congress hearing of impact of concussions on high school athletes

Research shows improved treatment of severe epilepsy reduces overall cost of the condition

FDA approves ZYMAXID ophthalmic solution for treatment of bacterial conjunctivitis

Studies suggest potent therapeutic effects of rufinamide in bipolar disorder, depressive and anxiety disorders

Columbia Laboratories renews license and supply agreement with Merck Serono

Final data from Open-Label studies of Cinryze in patients with HAE now available

Canadian tourist bitten by a Katipo spider in New Zealand

U.S. Well-Being Report for April 2010

Trubion Pharmaceuticals to present promising data from Phase 1 studies of SBI-087, SBI-087

Alexza Pharmaceuticals first-quarter net loss increases to $13.4 million

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Headache News and Research

Latest Headache News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in